panflu Stats

[Mixin]

The agreement aims to integrate cell-culture technology and know-how owned by or licensed to GSK and Kaketsuken (including the EB66(R) cell line in-licensed by GSK from Vivalis) with GSK's adjuvant technology in order to co-develop, manufacture and supply a cell-culture based pandemic influenza vaccine as early as possible in Japan.

With this collaboration, GSK and Kaketsuken are committed to contributing to Japan's pandemic plan through developing and making available as quickly as possible a cell-culture based pandemic influenza vaccine to as many people as possible in need of this vaccine.

Kaketsuken has been fulfilling its responsibilities of supplying seasonal influenza vaccines in Japan over the years and as a part of the country's pandemic response plan, it is manufacturing pandemic vaccine solutions for H5N1, contributing to the government's stockpiling. It is also currently manufacturing vaccines for the swine-derived H1N1 influenza that continues to spread.

http://www.genengnews.com/news/bnitem.aspx?name=64093502
_________________
https://twitter.com/mixin1771